INTRODUCTION: Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors. We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy. METHODS: Patients with MPM previously treated with a platinum-containing chemotherapy regimen and a performance status 0 to 2 were eligible for enrollment. Cediranib 45 mg/d was administered until progression or unacceptable toxicity. The primary end point was response rate. Tumor measurements were made by RECIST criteria, with a subset analysis conducted using modified RECIST. A two-stage design with an early stopping rule based on response rate was used. RESULTS: Fifty-four patients were enrolled. Of 47 evaluable patients, 4 patients (9%) had objective responses, 16 patients (34%) had stable disease, 20 patients (43%) had disease progression, 2 patients (4%) had symptomatic deterioration, and 1 patient (2%) had early death. The most common toxicities were fatigue (64%), diarrhea (64%), and hypertension (70%); 91% of patients required a dose reduction. Median overall survival was 9.5 months, 1-year survival was 36%, and median progression-free survival was 2.6 months. CONCLUSION: Cediranib monotherapy has modest single-agent activity in MPM after platinum-based therapy. However, some patient tumors were highly sensitive to cediranib. This study provides a rationale for further testing of cediranib plus chemotherapy in MPM and highlights the need to identify a predictive biomarker for cediranib.
INTRODUCTION:Malignant pleural mesothelioma (MPM) tumors express vascular epithelial growth factor (VEGF) and VEGF receptors. We conducted a phase II study of the oral pan-VEGF receptor tyrosine kinase inhibitor, cediranib, in patients with MPM after platinum-based systemic chemotherapy. METHODS:Patients with MPM previously treated with a platinum-containing chemotherapy regimen and a performance status 0 to 2 were eligible for enrollment. Cediranib 45 mg/d was administered until progression or unacceptable toxicity. The primary end point was response rate. Tumor measurements were made by RECIST criteria, with a subset analysis conducted using modified RECIST. A two-stage design with an early stopping rule based on response rate was used. RESULTS: Fifty-four patients were enrolled. Of 47 evaluable patients, 4 patients (9%) had objective responses, 16 patients (34%) had stable disease, 20 patients (43%) had disease progression, 2 patients (4%) had symptomatic deterioration, and 1 patient (2%) had early death. The most common toxicities were fatigue (64%), diarrhea (64%), and hypertension (70%); 91% of patients required a dose reduction. Median overall survival was 9.5 months, 1-year survival was 36%, and median progression-free survival was 2.6 months. CONCLUSION:Cediranib monotherapy has modest single-agent activity in MPM after platinum-based therapy. However, some patienttumors were highly sensitive to cediranib. This study provides a rationale for further testing of cediranib plus chemotherapy in MPM and highlights the need to identify a predictive biomarker for cediranib.
Authors: L Strizzi; A Catalano; G Vianale; S Orecchia; A Casalini; G Tassi; R Puntoni; L Mutti; A Procopio Journal: J Pathol Date: 2001-04 Impact factor: 7.996
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Kristian Pietras; Michael Stumm; Martine Hubert; Elisabeth Buchdunger; Kristofer Rubin; Carl-Henrik Heldin; Paul McSheehy; Markus Wartmann; Arne Ostman Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: Kristian Pietras; Kristofer Rubin; Tobias Sjöblom; Elisabeth Buchdunger; Mats Sjöquist; Carl-Henrik Heldin; Arne Ostman Journal: Cancer Res Date: 2002-10-01 Impact factor: 12.701
Authors: Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin Journal: Invest New Drugs Date: 2014-05-23 Impact factor: 3.850
Authors: Kaushal Parikh; Sumithra J Mandrekar; Katie Allen-Ziegler; Brandt Esplin; Angelina D Tan; Benjamin Marchello; Alex A Adjei; Julian R Molina Journal: Oncologist Date: 2019-12-24
Authors: Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly Journal: J Thorac Oncol Date: 2017-06-06 Impact factor: 15.609
Authors: Nicholas P Campbell; Rangesh Kunnavakkam; Natasha Leighl; Mark D Vincent; David R Gandara; Marianna Koczywas; Barbara J Gitlitz; Edem Agamah; Sachdev P Thomas; Walter M Stadler; Everett E Vokes; Hedy L Kindler Journal: Lung Cancer Date: 2012-07-23 Impact factor: 5.705